Procalcitonin as a prognostic factor in severe acute exacerbation of chronic obstructive pulmonary disease

Respirology

Volumn 14, Issue 7, 2009, Pages 969-974

  Rammaert, Blandine ^b   Verdier, Nicolas ^b   Cavestri, Béatrice ^b   Nseir, Saad ^a,b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

Author keywords

Acute exacerbation; Chronic obstructive pulmonary disease; Intensive care unit; Mechanical ventilation; Mortality; Procalcitonin

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; PROCALCITONIN;

ACUTE DISEASE; ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; BACTERIUM CULTURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY FAILURE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; INTUBATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; COHORT STUDIES; FEMALE; HUMANS; INTENSIVE CARE UNITS; INTUBATION, INTRATRACHEAL; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 70049117145     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2009.01597.x     Document Type: Article

References (32)

1. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004 364 : 613 620.
2. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007 370 : 741 750.
3. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur. Respir. J. 2006 27 : 397 412.
4. Soler JJ, Martinez-Garcia MA, Roman P, Salcedo E, Navarro M et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005 60 : 925 931.
5. Esteban A, Anzueto A, Frutos F, Alia I, Brochard L et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA 2002 287 : 345 355.
6. Maruna P, Nedelnikova K, Gurlich R. Physiology and genetics of procalcitonin. Physiol. Res. 2000 49 (Suppl. 1 S57 61.
7. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit. Care Med. 2008 36 : 941 952.
8. Christ-Crain M, Muller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur. Respir. J. 2007 30 : 556 573.
9. Daubin C, Parienti JJ, Vabret A, Ramakers M, Fradin S et al. Procalcitonin levels in acute exacerbation of COPD admitted in ICU: a prospective cohort study. BMC Infect. Dis. 2008 8 : 145.
10. Nseir S, Cavestri B, Di Pompeo C, Diarra M, Brisson H et al. Factors predicting bacterial involvement in severe acute exacerbations of chronic obstructive pulmonary disease. Respiration 2008 76 : 253 260.
11. Kruger S, Ewig S, Marre R, Papassotiriou J, Richter K et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur. Respir. J. 2008 31 : 349 355.
12. Niederman MS. Biological markers to determine eligibility in trials for community-acquired pneumonia: a focus on procalcitonin. Clin. Infect. Dis. 2008 47 (Suppl. 3 S127 32.
13. Stolz D, Christ-Crain M, Morgenthaler NG, Leuppi J, Miedinger D et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007 131 : 1058 1067.
14. Marquette CH, Georges H, Wallet F, Ramon P, Saulnier F et al. Diagnostic efficiency of endotracheal aspirates with quantitative bacterial cultures in intubated patients with suspected pneumonia. Comparison with the protected specimen brush. Am. Rev. Respir. Dis. 1993 148 : 138 144.
15. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. 2004 23 : 932 946.
16. Le Gall JR, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 1993 270 : 2957 2963.
17. McCabe WR, Jackson GG. Gram-negative bacteremia. Etiology and ecology. Arch. Intern. Med. 2009 110 : 847 855.
18. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease Accessed 4 April 2007.] Available from URL: http://www.goldcopd.com
19. Murphy TF, Brauer AL, Eschberger K, Lobbins P, Grove L et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2008 177 : 853 860.
20. Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2007 4 : 554 564. (Pubitemid 47547851)
21. Rammaert B, Ader F, Nseir S. Ventilator-associated pneumonia and chronic obstructive pulmonary disease. Rev. Mal. Respir. 2007 24 : 1285 1298.
22. Basi SK, Marrie TJ, Huang JQ, Majumdar SR. Patients admitted to hospital with suspected pneumonia and normal chest radiographs: epidemiology, microbiology, and outcomes. Am. J. Med. 2004 117 : 305 311.
23. Syrjala H, Broas M, Suramo I, Ojala A, Lahde S. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin. Infect. Dis. 1998 27 : 358 363.
24. Nseir S, Marquette CH. Diagnosis of hospital-acquired pneumonia: postmortem studies. Infect. Dis. Clin. North Am. 2003 17 : 707 716.
25. Boussekey N, Leroy O, Georges H, Devos P, d'Escrivan T et al. Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit. Infection 2005 33 : 257 263.
26. Ucgun I, Metintas M, Moral H, Alatas F, Yildirim H et al. Predictors of hospital outcome and intubation in COPD patients admitted to the respiratory ICU for acute hypercapnic respiratory failure. Respir. Med. 2006 100 : 66 74.
27. Nseir S, Di Pompeo C, Cavestri B, Jozefowicz E, Nyunga M et al. Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: prevalence, risk factors, and outcome. Crit. Care Med. 2006 34 : 2959 2966.
28. Liu SF, Lin KC, Chin CH, Chen YC, Chang HW et al. Factors influencing short-term re-admission and one-year mortality in patients with chronic obstructive pulmonary disease. Respirology. 2007 12 : 560 565.
29. Lin SH, Kuo PH, Hsueh PR, Yang PC, Kuo SH. Sputum bacteriology in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease in Taiwan with an emphasis on Klebsiella pneumoniae and Pseudomonas aeruginosa. Respirology 2007 12 : 81 7.
30. Ram FS, Picot J, Lightowler J, Wedzicha JA. Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2004 CD004104.
31. Coleta KD, Silveira LV, Lima DF, Rampinelli EA, Godoy I et al. Predictors of first-year survival in patients with advanced COPD treated using long-term oxygen therapy. Respir. Med. 2008 102 : 512 518.
32. Celli BR, Cote CG, Lareau SC, Meek PM. Predictors of Survival in COPD: more than just the FEV1. Respir. Med. 2008 102 (Suppl. 1 S27 35.